Ionis Pharmaceuticals, Inc.
Antisense compounds

Last updated:

Abstract:

Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.

Status:
Grant
Type:

Utility

Filling date:

9 Dec 2016

Issue date:

3 Dec 2019